What are ACE inhibitors, really?
ACE inhibitors — short for angiotensin-converting enzyme inhibitors — are a family of pills that lower blood pressure and protect the heart and kidneys by blocking one specific enzyme in your body. The class is one of the workhorses of modern cardiology. In the United States, lisinopril alone is among the top five most prescribed drugs of any kind, year after year.
The names you will run into are lisinopril (Zestril, Prinivil), enalapril (Vasotec, Epaned), ramipril (Altace), perindopril (Aceon, Coversyl), captopril (Capoten), fosinopril (Monopril), quinapril (Accupril), and benazepril (Lotensin). Cousins by mechanism, not identical twins. Some are active out of the box — captopril and lisinopril work as soon as you swallow them. Most others are prodrugs: they enter your bloodstream sleepy and the liver wakes them up. Enalapril has to be converted to enalaprilat before it does anything. That matters when the liver isn't well, which is why lisinopril, the one that bypasses the liver entirely, often wins out in patients with serious liver disease.
The origin story is one of the better ones in pharmacology. Captopril was synthesized in 1975 by Cushman and Ondetti at Squibb, inspired by the venom of the Brazilian pit viper Bothrops jararaca — a snake that drops its prey's blood pressure to nothing in seconds. A drug born from a snake's hunting mechanism is now sitting in millions of medicine cabinets.
How they work — the simple version
To understand ACE inhibitors you need a quick tour of a hormone system called RAAS — the renin-angiotensin-aldosterone system. The name is intimidating; the idea is not.
Think of RAAS as your body's emergency thermostat for blood pressure. When the kidneys sense pressure dropping — you stood up too fast, got dehydrated, lost blood — they release an enzyme called renin. Renin kicks off a chain reaction. A protein in your blood gets snipped into angiotensin I, which is fairly inert. Then a second enzyme — angiotensin-converting enzyme, or ACE — snips it one more time into angiotensin II, which is anything but inert. Angiotensin II is one of the most powerful vessel-squeezers your body makes. It tightens arteries, tells the kidneys to hold onto sodium and water, and prods the adrenal glands to release aldosterone, which holds onto even more sodium. Pressure up. Volume up. Crisis averted.
That system is brilliant if you are a hunter-gatherer who just gashed his leg. It is much less brilliant if you have heart failure, where the body misreads a struggling heart as "low pressure" and turns the thermostat up indefinitely. Vessels stay squeezed. The heart pushes harder against more resistance. Walls thicken. The whole system spirals.
ACE inhibitors are the off switch on the second snip. Block ACE, and angiotensin II collapses. Vessels relax, pressure falls, the kidneys stop hoarding sodium, the heart gets to push against less resistance. The thermostat that has been screaming at full volume goes back to a normal whisper.
There is a second piece of the same enzyme worth knowing about, because it explains half the side-effect profile. ACE has a day job and a night job. The day job is making angiotensin II. The night job (sometimes called kininase II) is breaking down a different molecule, bradykinin, which dilates vessels and tickles airway nerves. Block ACE and you block both jobs at once. Less angiotensin II, more bradykinin. The extra bradykinin is partly why these drugs lower blood pressure so well — and also why some people get a stubborn dry cough, and a small number get a rare but dangerous swelling reaction called angioedema. Not random allergic flukes. The mechanism telling on itself.
What else they do to your body, beyond lowering blood pressure
Once you understand that ACE inhibitors knock out two jobs of the same enzyme, the side-effect list stops being a random warning and starts being a logical map.
The dry cough. The most famous "I had to switch" complaint in cardiology. It hits roughly 5–35% of patients depending on the population, and is meaningfully more common in patients of East Asian ancestry than in patients of European ancestry. The cough is dry, persistent, worse at night, and not an infection. It is bradykinin and substance P piling up in the airways. It fades within one to four weeks of stopping. The fix, when the cough is intolerable, is almost always to switch to an ARB, which blocks the receptor downstream and leaves the bradykinin enzyme alone.
Angioedema. Same culprit, much more dangerous version. Bradykinin causes deep tissue swelling — face, lips, tongue, sometimes the throat. Less than 1% of patients overall, but several times more common in Black patients, which the 2017 ACC/AHA guidelines call out explicitly when choosing first-line therapy. The unsettling thing about ACE-inhibitor angioedema is that it can show up after years of uneventful use — it is not a "first dose" problem. If it happens, that drug, and as a class precaution the whole class, is off the table for life.
First-dose hypotension. When you finally lift the angiotensin-II foot off the gas, blood pressure can drop more than expected, especially in someone already volume-depleted — on loop diuretics, dehydrated from the flu, or in severe heart failure leaning hard on RAAS to maintain perfusion. That is why these drugs are typically started low, often at bedtime, and titrated up.
Hyperkalemia. Less angiotensin II means less aldosterone, which means the kidneys excrete less potassium. For most people this is a minor lab finding. For someone with reduced kidney function, on spironolactone, taking potassium supplements, or eating a heavy potassium load — it can climb fast enough to mess with the heart's electrical activity. That is why a creatinine and potassium check is standard a couple of weeks after starting.
The kidneys — the most misunderstood part. ACE inhibitors lower the pressure inside the glomerulus, the kidney's filtering unit. In someone with diabetes-driven kidney disease, that pressure has been chronically too high, slowly grinding the filter down. Lowering it protects the organ — that is why these drugs are foundational in diabetic nephropathy, proven by the landmark Lewis trial (NEJM, 1993). But there is a flip side: in bilateral renal artery stenosis, both kidneys are leaning on angiotensin II to keep filtering pressure high enough to work at all. Block angiotensin II, and the filter folds. Bilateral stenosis is an absolute contraindication. A small, gradual creatinine bump on starting is normal; a sharp jump is a red flag.
Pregnancy. Non-negotiable. ACE inhibitors are firmly contraindicated in the second and third trimesters because they damage fetal kidney development and reduce the amniotic fluid the baby needs to grow lungs. Anyone of childbearing age on this class needs a switch plan if pregnancy is on the table.
These are not bugs in a buggy drug. They are the same lever, viewed from different sides of the body.
What people usually take with them, and why
ACE inhibitors rarely fly solo. They are a foundation drug, and the rest of the regimen is built on top.
For high blood pressure. Major guidelines — the 2018 ESC/ESH guidelines (Williams et al.) and the 2017 ACC/AHA guidelines (Whelton et al.) — recommend them as a first-line class, especially in people with diabetes, chronic kidney disease, prior heart attack, or heart failure. When monotherapy isn't enough, standard pairings are with a calcium channel blocker (amlodipine and friends) or a thiazide-type diuretic. Each combination has a logic: ACE inhibitor + diuretic mops up sodium and relaxes vessels; ACE inhibitor + calcium channel blocker hits two different vessel-tightening mechanisms.
For heart failure with reduced ejection fraction (HFrEF). This is where ACE inhibitors changed cardiology. In 1987 the CONSENSUS trial showed enalapril cut six-month mortality by 40% in severe heart failure. Four years later SOLVD confirmed the benefit across a wider population. The 2021 ESC heart failure guidelines (McDonagh et al.) place an ACE inhibitor — or its successor combination drug sacubitril/valsartan — as one of the four foundational pillars of HFrEF therapy, alongside a beta-blocker (see our beta-blockers article), a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.
After a heart attack with reduced left ventricular function. The SAVE trial (Pfeffer et al., 1992) showed captopril cut mortality by about 19% and reduced new heart failure by more than a third. Ramipril did the same in HOPE (Yusuf et al., 2000) for high-cardiovascular-risk patients more broadly.
For diabetic kidney disease. Lewis et al. (1993) showed captopril roughly halved the risk of doubling serum creatinine in patients with type 1 diabetes and protein in the urine, independently of any blood-pressure effect. ACE inhibitors and ARBs have been the kidney-protective backbone in diabetes ever since.
A few combinations to be careful about:
- With an ARB. The intuition — block RAAS twice, get more benefit — was tested in the ONTARGET trial (Yusuf et al., 2008). The combination produced more low blood pressure, more kidney trouble, and more discontinuation, with no extra survival benefit. Routine dual RAAS blockade is no longer recommended.
- With aliskiren (a direct renin inhibitor) in patients with diabetes. The ALTITUDE trial was stopped early for harm. Contraindicated.
- With NSAIDs. They blunt the blood-pressure-lowering effect and pile on kidney risk. The combination of ACE inhibitor + NSAID + diuretic is famously called the "triple whammy" — three drugs ganging up on the kidneys at once, especially in older or dehydrated patients. If you are routinely on the ACE inhibitor, the casual ibuprofen habit deserves a second look. Our NSAIDs article goes deeper.
- With potassium-sparing diuretics or potassium supplements. Both push potassium up; ACE inhibitors push it up too. Monitoring essential.
- With lithium. ACE inhibitors raise lithium levels and can push them into the toxic range. Not forbidden, but watched closely.
The recurring theme: ACE inhibitors don't fight other drugs — they share a hallway with several of them, and the floor gets slippery if you don't pay attention.
Red flags — when to call a doctor
If you are on an ACE inhibitor, or just started one, and any of the following shows up — this is not a "let's see how it goes tomorrow" situation. This is a put-the-phone-down, call-a-doctor or go-to-the-ER situation.
- Sudden swelling of the face, lips, tongue, or throat. Trouble swallowing or breathing. That is angioedema. It can progress fast. Stop the drug and get to an emergency department now. The fact that you have been on the medication for years is not reassuring — angioedema can show up at any point.
- Severe lightheadedness, fainting, or your pressure dropping through the floor, especially after a first dose or after a dose increase. Sit down, get fluids, call your prescriber the same day.
- Sharply reduced urine output, swelling of the legs or face after starting, or your follow-up labs showing a big creatinine jump in the first weeks. That can be a sign of bilateral renal artery stenosis or another acute kidney process. Don't ignore it.
- Muscle weakness, palpitations, or an irregular heartbeat, which can be signs of high potassium. Particularly worth flagging if you are on spironolactone, eplerenone, or potassium supplements, or if your kidney function is reduced.
- Persistent dry cough that is wrecking your sleep. Not life-threatening, but not something to "tough out" for years either. There is a clean alternative — an ARB — and your prescriber has heard this complaint many times.
- You're pregnant or planning to be. This is a planned-conversation flag, not a 911 flag, but it is urgent enough that you should not wait until the next routine visit. A switch to a pregnancy-compatible regimen needs to happen.
- Yellowing of the skin or eyes, dark urine. Liver injury from ACE inhibitors is rare but documented; it warrants stopping and lab work.
A separate note for anyone managing someone elderly on this class: dehydration from a stomach bug, a heatwave, or simply not drinking enough on a long flight can tip a stable patient into acute kidney injury. The drug doesn't change; the body around it does. When in doubt, hold the dose for a day and call.
What people get wrong
"My blood pressure is fine now — I can stop the pill." The single most common mistake with any antihypertensive, and ACE inhibitors are no exception. Hypertension is chronic. The drug is keeping your numbers good; stop the drug and the numbers come back, usually within days to weeks. Stopping in heart failure is worse — it reverses the protective remodeling and brings symptoms back. The decision to stop or switch belongs to your prescriber, not to a glance at the home monitor.
"I got the cough, so I'm allergic — and I can never take ARBs either." The cough is not an allergy. It is a pharmacodynamic effect of bradykinin accumulation, specific to blocking ACE. ARBs work one step downstream, at the angiotensin II receptor, and they don't touch bradykinin metabolism. People with ACE-inhibitor cough almost always tolerate ARBs without a hitch. Angioedema is a different story — that is a hard "no" for both classes.
"ACE inhibitors are bad for the kidneys." This myth lands the patient backwards from where the evidence points. In diabetic nephropathy and proteinuric kidney disease, ACE inhibitors are protective — they slow progression to dialysis, as the Lewis trial showed. Yes, they need monitoring. Yes, they are dangerous in bilateral renal artery stenosis. But for the typical patient with diabetes, they are one of the few drugs that meaningfully delay losing the organ.
"They're all the same — give me whichever is cheapest." Cost is a legitimate factor and most are now generic. But "all the same" is too strong. They differ in half-life (captopril is multiple daily doses; ramipril and lisinopril are once-daily), in whether they need a working liver to activate, and in the evidence base behind specific uses. Ramipril carries the strongest post-MI and high-CV-risk evidence. Captopril, the strongest diabetic-nephropathy evidence. Enalapril and lisinopril are the heart-failure workhorses. The choice is rarely random.
"The first dose is just like any other dose." Usually, but not always. In someone severely dehydrated, on high-dose loop diuretics, or with tight RAAS-dependent perfusion, the first dose can drop pressure dramatically. Start low, sometimes at bedtime, titrate up — don't start at the target dose on day one.
"I have renal artery stenosis on one side, so the ACE inhibitor must be helping my kidneys." Unilateral stenosis is a different story than bilateral — the healthy kidney compensates. Bilateral stenosis is what turns ACE inhibitors from protective to dangerous.
"It's been a year with no problems — I don't need labs anymore." Annual checks of kidney function and potassium are standard regardless of how stable things look. The drug doesn't change. Your kidneys, your hydration, your other medications, and your salt intake all do.
ACE inhibitors are one of those rare drug classes that earned every line on their label twice over: enormous benefit in the right patient, real consequences in the wrong one. Knowing which side of that line you are on isn't paranoia — it is just using the drug the way it was designed to be used.